Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T62655 |
BET bromodomain inhibitor 2
|
||
BET bromodomain inhibitor 2 是一种 BET 型溴化域的有效抑制剂 (IC50: 14.1 μM)。 | |||
T6032 |
Birabresib
OTX-015,OTX015 (MK 8628/Birabresib),MK-8628 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
Birabresib (MK-8628) 是一种 BRD2/3/4抑制剂,IC50值为 92 到 112 nM 之间,具有潜在的抗肿瘤活性。 | |||
T3504 |
AZD5153 6-Hydroxy-2-naphthoic acid
AZD5153,AZD5153结晶体(API形式),AZD-5153 HNT salt |
Epigenetic Reader Domain | Chromatin/Epigenetic |
AZD5153 6-Hydroxy-2-naphthoic acid (AZD5153) 是 AZD5153的6-羟基-2-萘甲酸盐形式。AZD5153是一种有口服活性的选择性 BET/BRD4溴结构域抑制剂,对BRD4的IC50值为1.7nM。 | |||
T19618 |
(R)-(-)-JQ1 Enantiomer
(R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
(R)-(-)-JQ1 Enantiomer 是 (+)-JQ1 的立体异构体。 (+)-JQ1 是一种 BET 溴结构域抑制剂,对BRD4(1/2)的IC50 为 77 和 33 nM。 | |||
T19935 |
XD14
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
XD14 是BET 抑制剂,其与 BRD2、BRD3 和 BRD4 的结合常数分别为 170 nM、380 nM 和 160 nM。它具有抗肿瘤活性。 | |||
T10773 |
CF53
|
Epigenetic Reader Domain; CDK | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
CF53 是一种高效、选择性、可口服的 BET 抑制剂,对 BRD4 BD1 的 Ki 值为 <1 nM,Kd 值为 2.2 nM,IC50 值为 2 nM;CF53 对 BRD2,BRD3,BRD4 和 BRDT BET 蛋白的 BD1 和 BD2 两个结构域都有高亲和性,对其选择性远高于非含溴结构域 BET 蛋白。CF53 在体外和体内都具有显著的抗肿瘤活性。 | |||
T12558 |
PROTAC BET-binding moiety 2
|
Others | Others |
PROTAC BET-binding moiety 2 is an BET bromodomain inhibitor. | |||
T39998 |
BET bromodomain inhibitor 1
|
||
BET bromodomain inhibitor 1 is an orally active, selective inhibitor of bromodomain and extra-terminal (BET) proteins. It specifically inhibits BRD4 with an IC50 of 2.6 nM. Additionally, BET bromodomain inhibitor 1 demonstrates high affinities towards BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with Kd values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, and 2.1 nM, respectively. This compound exhibits anti-cancer activity. | |||
T74899 | GXH-II-052 | ||
GXH-II-052 是一种有效的二价 BET(bivalent bromodomain and extraterminal domain (BET))抑制剂。GXH-II-052 显示与 BRD4-1、BRD4-2、BRD4-T、BRDT-1、BRDT-2、BRDT-T 的结合潜力,Kd 值分别为 28、9.1、4.8、0.6、8.4、2.6 nM。GXH-II-052 显示出抗增殖活性。GXH-II-052 降低 c-Myc 的表达。 | |||
T74898 | NC-III-49-1 | ||
NC-III-49-1 是一种有效的二价 BET(bivalent bromodomain and extraterminal domain (BET))抑制剂。NC-III-49-1 显示与 BRD4-1、BRD4-2、BRD4-T、BRDT-1、BRDT-2、BRDT-T 的结合潜力,Kd 值分别为 0.095、0.32、0.29、0.089 、5.5、0.058 nM。NC-III-49-1 显示出抗增殖活性。NC-III-49-1 降低 c-Myc 的表达。 | |||
T36103 |
TW9
TW9 |
||
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μM) and for HDAC1 over HDAC2 (IC50= 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistica... |